Detalhe da pesquisa
1.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med;
390(4): 326-337, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38078508
2.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
3.
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.
Br J Haematol;
204(3): 784-804, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38247114
4.
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med;
384(11): 1028-1037, 2021 03 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33730455
5.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
6.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
24(5): 535-552, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37142374
7.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood;
137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33786588
8.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol;
2023 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36617990
9.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol;
23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35810754
10.
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Br J Haematol;
199(5): 707-719, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36017875
11.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply.
N Engl J Med;
390(17): 1634-1635, 2024 May 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38692304
12.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood;
135(15): 1204-1213, 2020 04 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31876911
13.
Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
Blood;
135(6): 411-428, 2020 02 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31794600
14.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Haematologica;
107(6): 1335-1346, 2022 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34587719
15.
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Eur J Haematol;
109(3): 197-204, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35390189
16.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29562156
17.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood;
133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30842083
18.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood;
133(26): 2765-2775, 2019 06 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30862645
19.
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Haematologica;
106(1): 230-237, 2021 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31949012
20.
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018.
Eur J Haematol;
107(2): 211-218, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34060690